Insmed rises as late‑stage trial backs wider use of lung disease drug

Insmed

23/03/2026 11:16

** Shares of drugmaker Insmed INSM.O rise 9.4% to $148.79 premarket

** Co says inhaled antibiotic Arikayce helped patients with MAC lung disease, a rare lung infection that causes long‑lasting cough, fatigue and breathing problems

** Says late‑stage study tested Arikayce with standard drugs in newly diagnosed patients

** Nearly 88% of patients cleared the infection by month six vs 57% on placebo; benefit lasted through month 15, co says

** Says main goal of the study is to help patients clear the lung infection and improve breathing symptoms

** Side effects such as cough and voice changes were more common; serious side effects seen in 14% vs 11% on placebo - INSM

** Co says it plans to seek U.S. and Japan approval to expand use of Arikayce later this year

** Shares rose about twofold in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))